Agios Pharmaceuticals (AGIO) Accumulated Expenses (2012 - 2026)

Agios Pharmaceuticals has reported Accumulated Expenses for 15 years, with the latest figure at $26.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 26.65% year-over-year to $26.3 million; the trailing twelve-month figure through Mar 2026 stood at $26.3 million (up 26.65% YoY), and the FY2025 full-year result was $45.5 million, down 2.99% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $26.3 million, down from $45.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $46.9 million in Q4 2024, with the low at $19.7 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $31.8 million across 5 years, with a median of $30.4 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses decreased 21.28% — and 2023, when it jumped 42.23%.
• Agios Pharmaceuticals' Accumulated Expenses stood at $30.4 million in 2022, then jumped by 42.23% to $43.2 million in 2023, then gained by 8.56% to $46.9 million in 2024, then dropped by 2.99% to $45.5 million in 2025, then slumped by 42.16% to $26.3 million in 2026.
• The last three Accumulated Expenses figures came in at $26.3 million (Q1 2026), $45.5 million (Q4 2025), and $37.2 million (Q3 2025), per Business Quant data.